To do so, we first examined effects of EPZ011989, an inhibitor of EZH2, a core subunit of the PRC2 complex [34], on expression of MHC‐I and antigen presentation machinery‐related genes in tRCC cells. This evidence concerns the gene EZH2 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.